Parallel, one of the largest privately held, vertically integrated, multi-state cannabis companies in the world, today appointed Walgreen’s veteran Jeremy Kunicki as its Chief Financial Officer (CFO), effective immediately. Parallel announced last week that it intends to become a public company through a definitive business combination agreement with Ceres Acquisition Corp., a special purpose acquisition corporation (SPAC). As CFO, Kunicki will lead Parallel’s finance and operations functions, as well as oversee corporate finance, shared services activities and operational management of the organization. James Whitcomb, who had served as Parallel’s Interim CFO, will continue in his role as Chief Development Officer.
Kunicki joins Parallel from Walgreens Boots Alliance, Inc. (NASDAQ: WBA), where he most recently served as CFO for the Walgreens division, one of the largest retail pharmacy companies in the United States. In this position, Kunicki led Walgreens’ finance team for the U.S. business and was responsible for financial oversight of investments, financial planning, performance management and business development. Throughout his 20 years at Walgreens, he played various finance leadership roles with a specific focus on operations, supply chain, real estate, digital and IT. Kunicki has also lead company-wide cost transformation programs, and oversaw finance for M&A integrations. Kunicki holds a Master of Accountancy from the University of Wisconsin-Madison.
“We are thrilled to welcome Jeremy to Parallel’s executive leadership team, especially at this momentous time for our company. Jeremy’s expertise in translating strategy into tangible corporate initiatives that drive growth will be a vital asset as Parallel continues to scale as a national cannabis well-being company. Most importantly, his community-focused values, passion for prioritizing consumer health and track record of building high performance teams align perfectly with our culture,” said William “Beau” Wrigley, Jr., Chief Executive Officer and Chairman of Parallel.
“I am excited to join Parallel as it prepares to become a publicly traded company. In a few short years, Parallel has differentiated itself as a leader in the cannabis industry, with strong revenue growth, an exceptional and seasoned leadership team, and a customer, community, and employee-centric vision,” said Jeremy Kunicki, CFO of Parallel. “I look forward to working with the Parallel team to pioneer consumer and patient well-being through the benefits of cannabinoids.”
Parallel is one of the largest privately held, vertically integrated, multi-state cannabis companies in the world with a mission to pioneer well-being and improve the quality of life through cannabinoids. Parallel owns and operates retail dispensaries in four medical and adult-use markets: Surterra Wellness in Florida and Texas; New England Treatment Access (NETA) in Massachusetts, and The Apothecary Shoppe in Nevada. Parallel also has a license under its Goodblend brand in Pennsylvania for vertically integrated operations and up to six retail locations, in addition to a medical cannabis research partnership with the University of Pittsburgh School of Medicine. The Company has a diverse portfolio of high quality, proprietary and licensed consumer brands and products including Surterra Wellness, Coral Reefer, Float and Heights. Parallel operates approximately 50 locations nationwide, including 42 retail stores and cultivation and manufacturing sites. The Company, through its wholly-owned Parallel Biosciences subsidiary, conducts advanced cannabis science and R&D for new product development in its facilities in Texas, Massachusetts, Florida, and Budapest, Hungary. Parallel follows rigorous operations and business practices to ensure the quality, safety, consistency and efficacy of its products and is building its business by following strong values and putting the well-being of its customers and employees first. Find more information at www.liveParallel.com, or onInstagram andLinkedIn.